ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

NCT07538401 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML) in

Interventions

DRUG: No high risk mutation
DRUG: High Risk Mutation

Sponsor

University Health Network, Toronto

Collaborators

[object Object]